About Jimena Vicencio
Articles by Jimena Vicencio, MD
FDA Grants Priority Review for Revumenib to Treat Relapsed or Refractory AMLSep 06, 2024
Making CAR-T Therapy Safer and More Accessible for DLBCL PatientsAug 29, 2024
EHA 2024: Ivosidenib for High-Risk MDS Patients Updated ResultsAug 26, 2024
How Does Lymphoma Show Up In Bloodwork?Aug 26, 2024
What You Need to Know About MyelofibrosisAug 23, 2024
What are the Differences Between MDS and AML?Aug 22, 2024
ASCO and EHA 2024 Updates for Multiple Myeloma PatientsAug 19, 2024
What Complications Are Common as Follicular Lymphoma Progresses?Aug 16, 2024
Support Treatment to Improve Daily Living with MDSAug 14, 2024
What’s Interferon's Role In Treating Myeloproliferative Neoplasms?Aug 14, 2024
Understanding High-Risk and Very-High-Risk MDSAug 14, 2024
Red Spots on the Skin, a Sign of Leukemia?Aug 13, 2024
What’s Better for High-Risk Multiple Myeloma? Cilta-cel vs Standard of CareAug 08, 2024
EHA 2024: Cevostamab for Relapsed and Refractory Multiple MyelomaAug 07, 2024
Is CLL Hereditary?Jul 30, 2024
Promising Results of Linvoseltamab in Relapsed/Refractory Myeloma: LINKER-MM1 StudyJul 29, 2024
EHA 2024: Bispecific Antibodies and New Advances in Myeloma Treatment with Dr. Ola LandgrenJul 24, 2024
What’s Genetic Testing in Multiple Myeloma?Jul 22, 2024
What Is Nonsecretory Multiple Myeloma?Jul 22, 2024
What Are The AML Types, and How Are They Classified?Jul 18, 2024
New Bispecific Antibody AZD0486 for Relapsed/Refractory LymphomaJul 17, 2024
Does AML Go to the Brain?Jul 08, 2024
Expert Discussion of MDS Risk AssessmentJul 08, 2024
BiTE Therapy Blinatumomab Now Approved as Consolidation Therapy for CD19 + Ph- B-ALLJul 03, 2024
